Investors begin new year with record loss

Investors lost a record Rs 13.3 lakh crore in the first fortnight of the current calendar year — the highest-ever in absolute terms. In percentage terms, the 3% decline was the second-highest in a decade.

Foreign portfolio investors (FPIs) were the primary drivers of the downturn, selling shares worth $4.9 billion (Rs 42,363 crore) during the period. On the other hand, domestic institutional investors (DIIs) provided much-needed support to the markets, purchasing shares worth Rs 49,367 crore.

Also ReadFormer Paytm directors settle case with SEBI for Rs 3.3 crore

Benchmark indices Sensex and Nifty declined nearly 2% each, while the broader BSE Midcap and BSE Smallcap indices fell 5.8% and 5.2%, respectively, in the first fortnight of 2025.

On Friday, the Sensex fell 423.49 points or 0.55% to close at 76,619.33, while the NSE Nifty declined 108.6 points or 0.47% to settle at 23,203.20. For the week, the benchmark indices posted losses of up to 0.98%, marking their second consecutive weekly decline, driven by an underperformance in large-cap IT and banking stocks.

Nuvama Institutional Equities predicts that slowing economic growth in India and declining earnings-growth expectations may bring Indian stocks in line with other emerging markets. A rising dollar and higher US Treasury yields have triggered foreign outflows, resembling a pattern last seen in 2018. This has also led to a liquidity crunch domestically, according to a report by Nuvama strategists Prateek Parekh and Jatin Somani, cited by Bloomberg.

“Investors are increasingly adopting a risk-averse stance due to dollar strengthening. Additionally, rising uncertainty over potential economic policies from the new U.S. administration has impacted overall sentiment,” said Vinod Nair, head of research, Geojit Financial Services.

The market is expected to remain cautious in the short term due to moderate Q3 expectations. Persistent FPI outflows could also contribute to higher volatility. Looking ahead, the policies and comments of the incoming US president, particularly on tariffs, will be closely monitored, Nair added.

The realty sector was the top loser during the fortnight, falling 10.2%, followed by consumer durables (down 5.9%), healthcare (down 5.8%), services (down 5.5%), and banking (down 4.9%).

Energy was the sole sectoral gainer, rising 1.59% during the period.

Also ReadUpcoming IPOs next week: 1 Mainboard and 3 SME IPOs open for subscription,  » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth